Fermer le menu

About us


Alizé Pharma 3 develops innovative
therapeutic peptides for rare endocrine
and metabolic diseases

Our ambition is to become a leading rare disease
company with U.S. and European operations to support
global development of our products


We are building an innovative and
balanced portfolio of products targeting
important unmet needs

Our first two assets are AZP-3601, a PTH analog for hypoparathyroidism, and AZP-3404, a peptide leveraging the biology of IGFBP2 for the treatment of severe insulin resistance syndromes


Alizé Pharma 3 is
the third venture within
the Alizé Pharma organization

The first two Alizé Pharma companies
were acquired by Jazz Pharmaceuticals (2016)
and Millendo Therapeutics (2017)


Thierry Abribat, Ph.D.

Founder and Chief Executive Officer

Thierry Abribat is a biotech entrepreneur who has founded and managed 3 biotech companies, one of which, Alizé Pharma 2, was acquired by Jazz Pharmaceuticals (Nasdaq: JAZZ) and, another, Alizé Pharma, was acquired by Millendo Therapeutics (Nasdaq: MLND). Prior to founding Alizé Pharma, he held several executive positions with increasing responsibilities in drug development, business development and management at Theratechnologies (TSX: TH) and at OPi, Pharmaceuticals for Rare Diseases, until OPi’s acquisition by EUSA Pharma Inc. Thierry began his career as a scientist for Sanofi, then at University of Montreal and as a consultant to the biopharmaceutical industry. He holds a Doctorate of Veterinary Medicine and a Ph.D. from the National Polytechnic Institute of Toulouse.

Michael Culler, Ph.D.

Chief Scientific Officer

Michael Culler brings over 35 years of research experience and is an internationally recognized expert in endocrinology, metabolic disorders and peptide therapeutics with over 200 publications and 22 patents.  He was formerly Vice President of Endocrinology Research for Ipsen, where he led programs in diverse endocrine/metabolic areas that resulted in six compounds reaching clinical development. Michael led the preclinical programs that produced the key assets for Rhythm Pharmaceuticals (relamorelin and setmelanotide), Tiburio Therapeutics (TBR-760 and 065), and Radius Pharma (abaloparatide; Tymlos®). He is a co-founder of Rhythm Pharmaceuticals and the scientific founder of Tiburio Therapeutics. Prior to joining industry, Michael conducted basic neuroendocrine research, both as a fellow at Tulane University School of Medicine and as a staff researcher at the National Institutes of Health.  In addition to his role as CSO for Alizé, Michael heads the Scientific Advisory Board for Tiburio, and is a member of the Expert List Committee of the World Anti-Doping Association (WADA).

Soraya Allas, M.D.

VP Clinical Development and Regulatory Affairs

Dr. Allas has a broad drug development background and extensive experience in strategic and operational roles in the biotech industry. Prior to joining Alizé Pharma 3, she was VP, Clinical Development for Millendo Therapeutics where she led the pivotal clinical development program of Unacylated Ghrelin analog livoletide in Prader-Willi syndrome (PWS). From 2010-2017, Soraya was Medical Director for Alizé Pharma where she led development and regulatory activities of all drug candidates, in particular livoletide from selection of lead through Phase 2a and Asparec®, a recombinant asparaginase. Prior to Alizé Pharma, she held leadership roles of increasing responsibilities in clinical development for endocrine and metabolic diseases at Theratechnologies that led to the approval of Growth Hormone Releasing Hormone analog Egrifta® for HIV-lipodystrophy. Dr. Allas holds an M.D. from the University of Algiers and a Ph.D. in biomedical sciences from the University of Montreal.


Patrick Loustau

Chief Business Officer

Patrick Loustau has over 25 years in global experience in developing and managing biotech and pharmaceutical companies. Prior to joining Alize Pharma 3, from 2017-2019, Patrick was the CEO of Zumbro Discovery, Inc., a clinical stage biotechnology company. From 2014-2016, he was the President of Zafgen, Inc., a Boston based biotechnology company focused on rare metabolic disease indications. Patrick was the SVP of Global Commercialization, Cardiovascular and Metabolics for Bristol-Myers Squibb from 2010-2014 and worked for 14 years for Novo Nordisk where he had several roles of increasing responsibility most recently as SVP Global Marketing and Medical Affairs. Mr. Loustau attended The General Manager Program, Harvard Business School and holds M.S. degrees in Human Resources/Marketing and in Psychology and a B.A. in Physiology.

Thomas Delale Ph.D.

VP, Portfolio Management

Thomas Delale is a biopharmaceutical professional with over 18 years of experience that spans from peptide drug discovery to late clinical stage development and corporate/business development. He has actively supported the creation of Alizé Pharma 3 as program and corporate development lead. Dr Delale was most recently Director, business development at Millendo Therapeutics (MLND). From 2010-2017, Thomas was the Innovation Manager for Alizé Pharma (acquired by Millendo Therapeutics) where he spearheaded livoletide (AZP-531) from discovery through Phase 2b/3 and supported Business Development and M&A activities. Prior to Alizé Pharma, he worked for the French Public Bank of Investment (Bpifrance). Thomas began his career as a scientist at the Schering-Plough Research Institute (now part of Merck & Co). Dr. Delale holds a Ph.D. in immunology from the University of Lyon and a M.S. from the Ecole Normale Supérieure de Lyon.

Delphine Martinez

General Counsel

Prior to joining Alizé Pharma 3, Delphine Martinez was the Head of Legal Affairs for ERYTECH, a clinical stage biopharmaceutical company developing innovative therapies for rare forms of cancer and orphan diseases. Over her 13-year tenure at ERYTECH, she had the opportunity to deal with a wide range of legal issues varying from contracts to intellectual property, corporate law and Human Resources matters.  Delphine contributed to all the development phases of the company from the establishment and the administration of its US subsidiary to its listing on stock exchange markets both on the Euronext and Nasdaq.  She began her career within the legal department of Opi (now part of EUSA Pharma).  Mrs Martinez holds a Master degree in International Business Law from the Jean Moulin University in Lyon and an M.B.A. from I.A.E. Lyon School of Management.


  • Felice Verduyn-van Weegen, Investment Manager at LSP, co-Chair
  • Naveed Siddiqi, Partner at Novo Ventures, co-Chair
  • Thierry Laugel, Managing Partner at Kurma Partners
  • Roy Amariglio, Principal at Orbimed
  • Iyona Rajkomar, Partner at Pontifax
  • Thierry Abribat, CEO Alizé Pharma 3
  • Mike Culler, CSO Alizé Pharma 3


  • René Kuijten, Managing Partner at LSP
  • Meredith Fisher, Partner at Partner Innovation Fund
  • Olivier Martinez, Senior Investment Director at Bpifrance
  • Mounia Chaoui, Associate Director at Turenne Santé

Our programs

AZP-3601, best-in-class PTH analog for hypoparathyroidism

Hypoparathyroidism, a severe disease resulting from insufficient parathyroid hormone (PTH) to maintain normal circulating calcium levels, affects over 80,000 patients in the US. It is associated with a large spectrum of symptoms, including mild to debilitating neuromuscular irritability, as well as neurocognitive and neuropsychiatric manifestations, due to low blood calcium levels.

AZP-3601 is a unique PTH analog designed specifically for PTH replacement therapy in hypoparathyroidism by academic partners at the Massachusetts General Hospital and Harvard Medical School. AZP-3601 potently interacts with a specific configuration of the PTH receptor that results in prolonged activation and effect on calcium metabolism. Preclinical studies have demonstrated that AZP-3601 is far more effective and longer-acting than natural PTH in increasing and maintaining circulating calcium levels without increasing urinary calcium excretion.

It is anticipated that the unique mechanism of action of AZP-3601 will translate into an enhanced safety and efficacy profile, and will make it a best-in-class therapy for treatment of this rare, but severe, endocrine disorder.


Key Academic Collaborators


Thomas J. Gardella – PhD
Associate Professor
in Medicine and Biochemiestry
MGH and Harvard Medical School




Michael Mannstadt – MD
Chief, Endocrine Unit MGH and
Associate Professor
Harvard Medical School


AZP-3404 for syndromes of severe insulin resistance

AZP-3404 is the first compound to harness the biology of Insulin-like Growth Factor Binding-Protein 2 (IGFBP-2), a physiological protein with key regulatory effects on glucose metabolism that are independent from its IGF-binding properties.

Alizé Pharma 3 and its academic partners at the University of North Carolina at Chapel Hill and the University of Maine have identified and optimized short peptide fragments of IGFBP-2 that retain its biological activities. AZP-3404 is a stabilized analog of one of these IGFBP-2 fragments with an improved pharmacokinetic profile. As a result, AZP-3404 is highly potent in restoring glucose control in preclinical models, including models of severe insulin resistance.

Based on its pharmacological profile, AZP-3404 is set to become a first-in-class therapy for the treatment of syndromes of severe insulin resistance, that include a range of rare diseases associated with high mortality and morbidity.


Key Academic Collaborators


David Clemmons – MD
University of North Carolina
at Chapel Hill (UNC)



Clifford Rosen – MD
Maine Medical center




Alizé Pharma 3 raises
€67 million ($75 million)
in Series A from a strong
international syndicate

En Fr


Alizé Pharma 3 to present data
from its AZP-3404 program
in syndromes of severe insulin
resistance at ENDO 2019

En Fr


Alizé Pharma 3 moves forward with building a transatlantic biopharmaceutical company focused on rare endocrine and metabolic diseases

En Fr

Contact us


Alizé Pharma 3

15, chemin du Saquin

Espace Européen, Building G

69 130 ECULLY



Tel +33 428 01 21 54